Abstracts

166 – Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV

Background Broadly neutralizing antibodies (bNAbs) against HIV-1 are in active clinical development. While they exhibit potent antiviral activity, their impact on the autologous HIV immune response remains unclear. The kinetics of autologous functional antibody responses during bNAb therapy have not been studied, as therapeutic and endogenous antibody effects are difficult to separate. To address this,…

167 – Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure

Background Autologous neutralizing antibodies (aNAbs) block outgrowth of substantial but variable fraction of reservoir viruses in people with HIV (PWH), and in rare early treated PWH, aNAbs can prevent viral rebound following treatment interruption. Here we characterized the aNAb response at the clonal level in a representative PWH who started treatment during chronic infection. Methods…

168 – In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention

Background Broadly neutralizing antibodies (bNAbs) are promising therapies against HIV-1 but require repeated infusions, limiting use in low- and middle-income countries with high HIV prevalence. The helper-dependent adenovirus (HDAd) gene therapy platform offers an accessible strategy for long-term therapeutic delivery with a one-time vector infusion. We developed the HDAd 6/3+ vector system to transduce nonhuman…

169 – Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials

Background Broadly neutralizing antibodies (bnAbs) target conserved regions of HIV Env. In clinical practice, HIV rapidly evolves to escape bnAbs via distinct resistance pathways, as described in recent clinical trials. Here, we delineate virus escape from VRC07-523LS in viremic rhesus macaques (RM) infected with a SHIV encoding a clade C Env.  Methods In a study…

170 – Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers

Background Following antiretroviral treatment (ART) interruption, people living with HIV (PLWH) exhibit diverse rebound kinetics including time to rebound, rebound slope, and control of viremia. To test if these differences are driven by the initial host immune response to rebounding virus, we conducted a highly sampled analytical treatment interruption (ATI) study focused on the time after ART…

128 – Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence and Safety Data in PURPOSE 1

Background Twice-yearly subcutaneous (SC) lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) showed high efficacy and a favorable safety profile in cisgender women in PURPOSE 1 (NCT04994509). We present updated HIV incidence, seroconversion, and safety data through the end of the randomized blinded phase. Methods PURPOSE 1 is an ongoing Phase 3, double-blind, active-controlled, randomized trial…

129 – Lenacapavir for PrEP: HIV-1 Incidence and Safety From PURPOSE 2 at End of Randomized Blinded Phase

Background PURPOSE 2 (NCT04925752) demonstrated the high efficacy and safety of twice-yearly subcutaneous (SC) lenacapavir (LEN) for pre-exposure prophylaxis (PrEP) in cisgender men and gender-diverse individuals who have sex with partners assigned male at birth and who are disproportionately affected by HIV. We report updated HIV incidence and safety data through the end of the randomized…